Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127689 | 0.88 | ERN1 (0.53) | ERN1PRKDCLMNAMEN1HSP90AA1 | |
| SCHEMBL12584035 | 0.80 | PRKDC (0.42) | ERN1PRKDCLMNAMEN1KMT2A | |
| SCHEMBL12143391 | 0.80 | ERN1 (0.47) | ERN1PRKDC | |
| SCHEMBL31629396 | 0.79 | ERN1 (0.54) | ERN1PRKDC | |
| SCHEMBL2457983 | 0.78 | ERN1 (0.52) | ERN1CYP3A4TSHRMAPTALDH1A1 | |
| SCHEMBL2921541 | 0.78 | ERN1 (0.52) | ERN1PRKDCCYP3A4HIF1ASIRT1 | |
| SCHEMBL1303936 | 0.75 | ERN1 (0.72) | ERN1PRKDC | |
| SCHEMBL28123711 | 0.75 | ERN1 (0.52) | ERN1TSHRALDH1A1 | |
| SCHEMBL1193233 | 0.74 | ERN1 (0.63) | ERN1SIRT1 | |
| SCHEMBL30689085 | 0.74 | ERN1 (0.63) | ERN1SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238170-A1 | 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-05 | — | — | US | disclosed |
| EP-2968258-B1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019215633-A1 | 5,5-DIFLUORO- AND 5-FLUORO-5-METHYL-C-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | WO | disclosed |
| US-9012412-B2 | Dual SGLT1/SGLT2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-21 | — | — | US | disclosed |
| US-9012412-B2 | Dual SGLT1/SGLT2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-21 | — | — | US | disclosed |
| WO-2014164286-A1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | SLC5A1, SLC5A2, GLP1R | ERN1 1905/4885PRKDC 4791/4885LMNA 4631/4885 |
| US-20210238170-A1 | 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators | SLC5A2, SLC5A1, SLC2A4 | ERN1 3950/4885PRKDC 4179/4885LMNA 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.